Flag of the European Union EU Clinical Trials Register Help

Clinical trials for SLE

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    229 result(s) found for: SLE. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-002179-34 Sponsor Protocol Number: SLE01_ENK Start Date*: 2005-08-10
    Sponsor Name:Euro Nippon Kayaku GmbH
    Full Title: SAFETY AND EFFICACY STUDY ON DEOXYSPERGUALIN (NKT-01) IN PATIENTS WITH UNCONTROLLED LUPUS NEPHRITIS RECEIVING ORAL CORTICOSTEROIDS AND PRIOR TREATMENT OF STANDARD IMMUNOSUPPRESSIVE THERAPY - a pros...
    Medical condition: Systemic lupus erythrematosus (SLE) is an aggressive autoimmune disease. The chronic inflammatory processes involve many organs like the skin, lung, kidneys, central and peripheral nervous system, ...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10025140 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003814-18 Sponsor Protocol Number: HGS1006-C1115 Start Date*: 2012-05-03
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys...
    Medical condition: Systemic lupus erythematosis (SLE)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10042944 Systemic lupus erythematosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) AT (Completed) CZ (Completed) SE (Completed) BE (Completed) PT (Completed) ES (Completed) DK (Completed) GB (Completed) BG (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2025-000106-42 Sponsor Protocol Number: 213560 Start Date*: 2025-04-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Protocol Title: A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients with Active Systemic Lupus Eryth...
    Medical condition: Active Systemic Lupus Erythematosus (SLE)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-004047-86 Sponsor Protocol Number: AIS-A03 Start Date*: Information not available in EudraCT
    Sponsor Name:Alpine Immune Sciences, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPN-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10042946 Systemic lupus erythematosus rash PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042948 Systemic lupus erythematosus syndrome aggravated LLT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042947 Systemic lupus erythematosus synd LLT
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    20.1 10022891 - Investigations 10067657 Systemic lupus erythematosus disease activity index increased PT
    20.0 10022891 - Investigations 10067658 Systemic lupus erythematosus disease activity index decreased PT
    20.1 10022891 - Investigations 10067659 Systemic lupus erythematosus disease activity index abnormal PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10080670 Systemic lupus erythematosus reactivation LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10073694 Lupus pleurisy PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10040968 SLE arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) ES (Prematurely Ended) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001391-12 Sponsor Protocol Number: TV-4710/201 Start Date*: 2005-07-27
    Sponsor Name:TEVA Pharmaceutical Industries, Ltd.
    Full Title: A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10042945 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005027-25 Sponsor Protocol Number: I4V-MC-JAIA Start Date*: 2018-09-21
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-004852-62 Sponsor Protocol Number: FARM7KWBZ4 Start Date*: 2009-02-09
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
    Full Title: Safety and clinical efficacy of abetimus sodium (LJP-394) in prevention of renal flares in patients with systemic lupus erythematosus and a history of renal disease.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028395 SOC
    9.1 10040970 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005672-42 Sponsor Protocol Number: HGS1006-C1112 Start Date*: 2013-06-11
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10025134 Lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000368-88 Sponsor Protocol Number: BEL114055 Start Date*: 2012-06-13
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta...
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) NL (Ongoing) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004404-21 Sponsor Protocol Number: SLE-Omega Start Date*: 2004-12-10
    Sponsor Name:GreenPark Healthcare Trust [...]
    1. GreenPark Healthcare Trust
    2. Queens University Belfast
    Full Title: Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences
    Medical condition: Systemic Lupus Erythematosus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011245-55 Sponsor Protocol Number: 09575704 Start Date*: 2009-05-06
    Sponsor Name:Active Biotech Research AB
    Full Title: An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 20...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004404-35 Sponsor Protocol Number: I4V-MC-JAHH Start Date*: 2016-04-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)
    Medical condition: Patients with Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PL (Completed) ES (Completed) FR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-018329-20 Sponsor Protocol Number: LN-LAQ-201 Start Date*: 2010-05-07
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combinati...
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025140 Lupus nephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005177-21 Sponsor Protocol Number: HGS1006-C1056 Start Date*: 2007-05-29
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042945 Systemic lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) AT (Completed) CZ (Completed) ES (Completed) SK (Completed) SE (Completed) NL (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022099-29 Sponsor Protocol Number: H9B-MC-BCDS Start Date*: 2011-07-04
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMIN...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed) IT (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000594-69 Sponsor Protocol Number: 211LE202 Start Date*: 2014-06-20
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects with Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed) PL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002205-22 Sponsor Protocol Number: IM014029 Start Date*: 2020-05-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: "A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögr...
    Medical condition: SLE Sub-protocol: Systemic Lupus Erythematosus pSS Sub-protocol: Primary Sjögren’s Syndrome RA Sub-protocol: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) ES (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001508-12 Sponsor Protocol Number: CVAY736X2208 Start Date*: 2018-11-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VA...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000674-73 Sponsor Protocol Number: LJP 394-90-14 Start Date*: 2006-08-11
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOS...
    Medical condition: Systemic lupus erythematosus patients with a history of renal disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042945 Systemic lupus erythematosus LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001269-40 Sponsor Protocol Number: CT-1306 Start Date*: 2008-10-29
    Sponsor Name:Charité University Medicine
    Full Title: Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Th...
    Medical condition: Patients with systemic lupus erythematosus (SLE) will be under investigation who show high disease activity despite treatment with standard immunosuppressive therapies: high-dose corticosteroids an...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:55:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA